Welcome to our dedicated page for Transcode Therapeutics news (Ticker: RNAZ), a resource for investors and traders seeking the latest updates and insights on Transcode Therapeutics stock.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) generates a steady flow of news as a clinical-stage oncology company advancing RNA-targeted therapeutics for cancer. This news page aggregates press releases and third-party coverage related to TransCode’s development programs, corporate actions, and scientific collaborations, giving readers a centralized view of how the company’s RNA oncology strategy is progressing.
Much of the company’s news focuses on its lead candidate, TTX-MC138, an RNA-based therapeutic designed to inhibit microRNA-10b (miR-10b), which TransCode identifies as a key factor in metastatic cancer. Updates include milestones from its Phase 0 and Phase 1a clinical trials in metastatic solid tumors, reports on safety and pharmacodynamic data, and announcements about advancing TTX-MC138 into Phase 2a studies across selected metastatic indications and minimal residual disease settings.
Readers can also follow news about preclinical research using the TTX platform, such as studies in glioblastoma models demonstrating delivery of TTX-MC138 to brain tumors, target engagement, and extended survival in murine models. These items highlight how TransCode’s nanoparticle platform is being evaluated for systemic delivery of RNA therapeutics to challenging tumor sites.
Beyond clinical and preclinical data, TransCode’s news includes corporate and strategic developments, such as the acquisition of Polynoma and the addition of seviprotimut-L, a polyvalent shed antigen vaccine for stage IIB and IIC melanoma, to its pipeline. Filings and releases also cover financing transactions with affiliates of CK Life Sciences, reverse stock split decisions related to Nasdaq listing requirements, and governance updates including board and executive appointments.
For investors, researchers, and clinicians, following RNAZ news offers insight into TransCode’s progress in metastatic disease, its expanding immuno-oncology and RNA pipeline, and the regulatory and capital markets events that shape its development path. Bookmark this page to review new trial readouts, platform data, and transaction announcements as they are released.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) announced that an interview with CEO Michael Dudley will be broadcasted on The RedChip Money Report® on Bloomberg TV on March 26 at 7 p.m. ET. The report aims to provide insights into small-cap investing and features financial commentary and public company interviews. TransCode focuses on RNA therapeutics to combat cancer, with lead candidate TTX-MC138 targeting metastatic cancer. This condition accounts for about 90% of cancer deaths globally, totaling over nine million annually.
TransCode Therapeutics (NASDAQ: RNAZ) published an article in Cancers discussing the advancements in short RNA-based therapeutics for cancer and other diseases. Co-authored by Dr. Anna Moore, the article explores the design, modification, and delivery of these RNA drugs. Key insights include the potential of RNA therapeutics to revolutionize treatment methods, particularly in personalized cancer therapy. CEO Michael Dudley announced plans for a first-in-human trial of the lead candidate, TTX-MC138, aimed at targeting metastatic disease, which accounts for 90% of cancer deaths.
TransCode Therapeutics, Inc. (NASDAQ: RNAZ) has filed an International PCT Application (PCT/US21/65580) for its novel cancer therapy entitled TEMPLATE DIRECTED IMMUNOMODULATION FOR CANCER THERAPY. This application expands the company's RNA therapeutic platform to activate the RIG-I signaling pathway, potentially leading to tumor cell death and enhancing the immune response against cancer. The patent aims to allow for personalized cancer treatments using TransCode's TTX delivery platform, which targets various RNA therapies for different tumor types.
TransCode Therapeutics (Nasdaq: RNAZ) has announced its participation at the 2022 BIO CEO & Investor Conference, scheduled for February 14-17, 2022. CEO Michael Dudley will present the company's RNA-based innovations aimed at combating cancer, particularly highlighting the lead candidate, TTX-MC138, intended for metastatic disease treatment. An exploratory Investigational New Drug (eIND) application with the FDA is expected to be filed in the second half of 2022 to initiate a first-in-human trial for Stage IV breast cancer patients.
TransCode Therapeutics (RNAZ) is set to present at the 2022 BIO CEO & Investor Conference from February 14-17, 2022. CEO Michael Dudley will discuss the company's RNA-based innovations aimed at advancing cancer treatment, particularly their lead candidate for metastatic disease. An exploratory Investigational New Drug application (eIND) is expected to be filed with the FDA in the second half of 2022, paving the way for a First-in-Human clinical trial targeting Stage IV breast cancer. The presentation will be streamed live and available for later viewing.
BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) will attend and present at the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Michael Dudley will discuss the company's RNA-based cancer treatments, focusing on its lead candidate, TTX-MC138, which aims to enter its First in Human clinical trial in 2022. The presentation is scheduled for January 10, 2022, at 7:00 AM ET and will be webcast, with an archived recording available for 90 days on TransCode's website.
BOSTON, Dec. 06, 2021 (GLOBE NEWSWIRE) -- TransCode Therapeutics (Nasdaq: RNAZ) announced its participation at the MedInvest Oncology Investor Conference. CEO Michael Dudley will present the company's RNA-based advancements in cancer treatment, including their lead candidate, TTX-MC138, targeting metastatic cancer with a first human trial expected in mid-2022. The presentation is scheduled for December 7th at 2:50 PM EST and will be available via webcast. TransCode aims to improve outcomes for various cancers, responsible for approximately 90% of cancer deaths globally.
TransCode Therapeutics (RNAZ) reported progress in its RNA oncology initiatives and released its Q3 2021 financials. The company anticipates filing an eIND for TTX-MC138 by mid-2022. Extensive clinical data from microdosing studies supports the efficacy of TTX-MC138, designed for metastatic tumors. Financially, the company reported cash and equivalents of approximately $22.5 million, up from $0.8 million year-over-year, with significant increases in R&D and G&A expenses. Net loss for Q3 2021 was approximately $2.3 million, or $0.20 per share, and the company expects to continue incurring losses.
TransCode Therapeutics, Inc. (RNAZ) has appointed Dr. Zdravka Medarova as Chief Technology Officer, effective October 1, 2021. A scientific co-founder, Dr. Medarova has been on the advisory board since 2016 and brings expertise in RNA oncology, specifically in developing nanotechnology for RNA delivery. Her leadership is expected to enhance the TTX delivery platform, pivotal for TransCode's cancer treatment innovations. The company focuses on treating metastatic cancers, which account for approximately 90% of cancer deaths globally, with potential first-in-human studies ahead.
TransCode Therapeutics announced the publication of preclinical research supporting its lead candidate, TTX-MC138, in Cancer Nanotechnology. The study demonstrated that TTX-MC138 effectively targets metastatic lesions in models of metastatic breast cancer. Results showed successful biodistribution and pharmacokinetics, with TTX-MC138 accumulating in metastatic areas when administered intravenously. The company plans to submit an exploratory IND application in Q1 2022 for a Phase 0 study to establish clinical proof-of-concept, utilizing new microdosing PET-MRI methods to further advance its RNA delivery platform.